Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented (SABCS), being held December 10-13, 2024, in San Antonio, Texas.

Treatment of early-stage HER2-positive breast cancer is similar to that of HER2-negative breast cancer, but it usually also includes a HER2-targeted drug such as Herceptin. A lumpectomy or ...

In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...

Breast cancer is classified into several subtypes depending on the presence or absence of the patient's factors.

Plus Therapeutics subsidiary CNSide Diagnostics has reported data from the multi-centre FORESEE trial, which highlights the ...

Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of ...

The approval of Ziihera offers a chemotherapy-free treatment alternative for patients with previously-treated, unresectable or metastatic HER2-positive ... with a negative gross profit of $ ...